Iron deficiency and supplementation in heart failure and chronic kidney disease

Shweta Punj, Kambiz Ghafourian, Hossein Ardehali*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Iron is a key element for normal cellular function and plays a role in many cellular processes including mitochondrial respiration. The role of iron deficiency (ID) in heart failure (HF) has been a subject of debate amid increasing advocacy for intravenous (IV) supplementation. Both the definition and the approach to treatment of ID in HF have been adapted from the experience in patients with chronic kidney disease (CKD). In this review, we highlight the differences in regulatory mechanisms as well as pathophysiology of ID in CKD and HF population both at the systemic and cellular levels. We will review the major clinical trials in HF patients that have shown symptomatic benefit from IV iron supplementation but without effect on clinical outcomes. Intravenous iron loading bypasses the mechanisms that tightly regulate iron uptake and can potentially cause myocardial and endothelial damage by releasing reactive oxygen species. By contrast, newer oral iron preparations do not have similar toxicity concerns and might have a role in heart failure.

Original languageEnglish (US)
Article number100873
JournalMolecular Aspects of Medicine
Volume75
DOIs
StatePublished - Oct 2020

Keywords

  • Chronic kidney disease
  • Heart failure
  • Intravenous iron
  • Iron deficiency

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Iron deficiency and supplementation in heart failure and chronic kidney disease'. Together they form a unique fingerprint.

Cite this